# Keythera Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keythera-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.keytherapharma.com
- Total disclosed funding: $30M
- Latest round: Series A (Mar 22, 2021)
- Investors on record: 6

## About

Keythera Pharmaceuticals, established in 2018 and based in Suzhou, China, focuses on the development of innovative small molecule drugs targeting oncology and autoimmune diseases.Keythera Pharmaceuticals is involved in the research and development of groundbreaking therapeutic solutions. Founded in 2018 in Suzhou, China, by Yongqi Deng, the company has raised a total of CNY 100.000 mn through 2 funding deals, with the latest being a Series A round led by Yijing Investment on March 22, 2021, featuring participation from Entropy Asset Management and Trend Investment Group.Keythera Pharmaceuticals specializes in innovative small molecule drugs primarily aimed at treating oncology and autoimmune conditions. Its leading products include the EP4 receptor antagonist KF-0210, which is in Phase Ib clinical trials for solid tumors and has approved Phase II trials for osteoarthritis, and KBP-2205, focused on cancer treatment and having completed PCC validation studies. These products are based on the company’s proprietary Affinity Detection by Mass Spectroscopy (ADMS) platform, designed for high-throughput screening. Keythera serves healthcare providers and research institutions across China and potentially in international markets as it advances its clinical trials.Keythera Pharmaceuticals operates a revenue model centered on the development and commercialization of its pharmaceutical products through clinical trials and regulatory approvals. The company collaborates with healthcare institutions and pharmaceutical companies through research agreements and licensing deals. Revenue is anticipated from its flagship products, KF-0210 and KBP-2205, with structured agreements that include milestone payments and royalties, creating a flow of income from upfront partnerships and ongoing royalties upon market entry.Keythera Pharmaceuticals plans to advance its pipeline with the ongoing development of KF-0210 and KBP-2205, targeting a broader range of oncology applications and exploring new indications by 2023. The recent Series A funding round of CNY 100.000 mn will support these initiatives, allowing the company to enhance its clinical trial capabilities and expand its research operations into international markets, thereby broadening its commercial footprint.

## Funding rounds

- Series A, Mar 22, 2021, $15M — Trend Investment Group, Yijing Investment, Entropy Asset Management
- Series A, Sep 28, 2020, $15M — Oriza Holdings, Ming Bioventures, Huaige Capital, Entropy Asset Management

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- Entropy Asset Management — Series A
- Trend Investment Group (https://capitalatlas.ai/funds/trend-investment-group) — Series A
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A